

IN THE CLAIMS:

Please cancel claim 26 without prejudice or disclaimer. In accordance with 37 CFR § 1.121, please substitute for original claims 25 and 27, the following rewritten versions, as amended. The changes are shown explicitly in the attached "Marked-Up Version Of The Claims."

C1
25. (Once amended) The method of claim 24 wherein the tyrosine kinase receptors are chosen from the group consisting of the *KDR/flk-1* receptor, the *flt-1* receptor, and/or the *tek/tie-2* receptor.

C2
27. (Once amended) The method of claim 25, wherein the site distal from a primary tumor is a body fluid selected from the group consisting of urine, lymph and cerebrospinal fluid.